SRX251, or SRX-251, also known as API-251, is a selective vasopressin V1A receptor antagonist that is or was under development for the treatment of aggression.

[1][2] SRX251 reduces aggressive behavior in rodents.

[4][2] It is or was being developed by Azevan Pharmaceuticals.

[1][3] In 2007, it was in phase 1 clinical trials.

[1][3] This psychoactive drug-related article is a stub.